<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02039765</url>
  </required_header>
  <id_info>
    <org_study_id>863/13-100-0007</org_study_id>
    <nct_id>NCT02039765</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.</brief_title>
  <official_title>A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in Healthy, Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the plasma pharmacokinetics and safety profile of brimonidine following a
      single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution
      0.025% for 7 days in healthy, adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Levels</measure>
    <time_frame>Day 1 (Visit 2)</time_frame>
    <description>Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Levels</measure>
    <time_frame>Day 2 (Visit 3)</time_frame>
    <description>Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Levels</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Levels</measure>
    <time_frame>Day 8 (Visit 5)</time_frame>
    <description>Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Visual acuity testing should be done with best correction at 10ft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Biomicroscopy</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>Day 8 (Visit 5)</time_frame>
    <description>Intraocular Pressure measured at baseline Day 8 (Visit 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology and Blood Chemistry Analysis</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Blood samples will be collected for hematology and blood chemistry parameters at Baseline (Visit 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Urine sample will be collected for urinalysis at Baseline (Visit 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Day 1 (Visit 2)</time_frame>
    <description>Visual acuity testing should be done with best correction at 10ft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Visual acuity testing should be done with best correction at 10ft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Day 8 (Visit 5)</time_frame>
    <description>Visual acuity testing should be done with best correction at 10ft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Biomicroscopy</measure>
    <time_frame>Day 1 (Visit 2)</time_frame>
    <description>Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Biomicroscopy</measure>
    <time_frame>Day 7 (Visit 4)</time_frame>
    <description>Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Biomicroscopy</measure>
    <time_frame>Day 8 (Visit 5)</time_frame>
    <description>Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of 0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>Baseline (Visit 1)</time_frame>
    <description>Intraocular Pressure measured at baseline (Visit 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology and Blood Chemistry Analysis</measure>
    <time_frame>Day 8 (Visit 5)</time_frame>
    <description>Blood samples will be collected for hematology and blood chemistry parameters at Day 8 (Visit 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Day 8 (Visit 5)</time_frame>
    <description>Urine sample will be collected for urinalysis at Day 8 (Visit 5)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hyperemia</condition>
  <arm_group>
    <arm_group_label>Brimonidine tartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine tartrate</intervention_name>
    <arm_group_label>Brimonidine tartrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have ocular health within normal limits.

          -  have blood (hematology, blood chemistry) and urine analysis within normal limits.

          -  have a body weight within 15% of ideal weight

        Exclusion Criteria:

          -  have known contraindications or sensitivity to the use of any of the investigational
             drug(s) or their components, or any other medications required by the protocol;

          -  have any active systemic or ocular disorder other than refractive disorder.

          -  have presence of any abnormality of the lids, ocular surface, or lacrimal duct system
             that in the Investigator's opinion could affect ophthalmic drop absorption.

          -  have a history of chronic alcohol consumption.

          -  consume alcohol and/or caffeine or xanthine containing products within 48 hours prior
             to dosing at Visit 1 or anticipated use during the study.

          -  have a history of tobacco, nicotine, or nicotine containing product use within the
             last year prior to Visit 2;

          -  have significant weight change (over 10 pounds) within the 60 days prior to Visit 2;

          -  have blood donation or equivalent blood loss of 450 ml or more, within 60 days prior
             to Visit 2;

          -  have an abnormal blood pressure (defined as ≤ 90 or ≥ 160 (systolic) measured in mmHg
             or ≤ 60 or ≥ 100 (diastolic) measured in mmHg);

          -  have intraocular pressure (IOP) that is less than 5 mmHg or greater than 22 mmHg or
             have a normal IOP with a diagnosis of glaucoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Ciolino, MD</last_name>
    <role>Study Director</role>
    <affiliation>ORA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb, Incorporated</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular Redness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

